Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Saved in:
| Title: | Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. |
|---|---|
| Authors: | Hutton DW; University of Michigan School of Public Health, Ann Arbor., Glassman AR; Jaeb Center for Health Research, Tampa, Florida., Liu D; Jaeb Center for Health Research, Tampa, Florida., Sun JK; Joslin Diabetes Center, Beetham Eye Institute, Department of Ophthalmology, Harvard University, Boston, Massachusetts. |
| Corporate Authors: | DRCR Retina Network |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2023 Mar 01; Vol. 141 (3), pp. 268-274. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6173 |
|---|---|
| DOI: | 10.1001/jamaophthalmol.2022.6142 |
